Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | MMP1 | P03956 | 1/20 | 0.53 |
| ▸ | MMP3 | P08254 | 1/20 | 0.53 |
| ▸ | MMP7 | P09237 | 1/20 | 0.53 |
| ▸ | MMP9 | P14780 | 1/20 | 0.53 |
| ▸ | MMP13 | P45452 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.45 |
| ▸ | FPR2 | P25090 | 1/20 | 0.45 |
| ▸ | CSGALNACT1 | Q8TDX6 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1636005 | 1.00 | MMP2 (0.53) | MMP2MAPK1MMP1MMP3MMP7 | |
| SCHEMBL11062013 | 0.84 | MMP2 (0.44) | MMP2MAPK1MMP1MMP3MMP7 | |
| SCHEMBL11196494 | 0.83 | ADAMTS4 (0.51) | MMP2MMP9CA12FPR2GAA | |
| SCHEMBL11193293 | 0.83 | MMP9 (0.51) | MMP2MMP1MMP3MMP7MMP9 | |
| SCHEMBL11193286 | 0.83 | MMP9 (0.51) | MMP2MMP1MMP3MMP7MMP9 | |
| SCHEMBL11196490 | 0.83 | ADAMTS4 (0.51) | MMP2MMP9CA12FPR2GAA | |
| SCHEMBL2159137 | 0.82 | LMNA (0.59) | MMP2MMP1MMP3MMP7MMP9 | |
| SCHEMBL8745550 | 0.82 | LMNA (0.59) | MMP2MMP1MMP3MMP7MMP9 | |
| SCHEMBL2159141 | 0.82 | LMNA (0.59) | MMP2MMP1MMP3MMP7MMP9 | |
| SCHEMBL11061860 | 0.81 | MMP2 (0.53) | MMP2MAPK1MMP1MMP3MMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932277-B2 | Peptide inhibitors of hepatitis C virus replication | INTERMUNE, INC. (US) | 2011-04-26 | — | — | US | disclosed |
| EP-2185524-A1 | NOVEL PEPTIDE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | Intermune, Inc. (US) | 2010-05-19 | — | — | EP | disclosed |
| CN-101679277-A | Novel peptide inhibitors of hepatitis c virus replication | INTERMUNE INC | 2010-03-24 | — | — | CN | disclosed |
| US-20090297476-A1 | NOVEL PEPTIDE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| WO-2008141227-A1 | NOVEL PEPTIDE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2008-11-20 | — | — | WO | disclosed |
| US-4464307-A | Substituted acid chloride process | ZOECON CORPORATION (US) | 1984-08-07 | — | — | US | disclosed |
| US-4411912-A | Insecticidal isovaleric acid esters | ZOECON CORPORATION (US) | 1983-10-25 | — | — | US | disclosed |
| US-4243819-A | Substituted amino acids | ZOECON CORPORATION (US) | 1981-01-06 | — | — | US | disclosed |
| US-4231953-A | Fluoro substituted aryl esters and thiolesters of amino acids | ZOECON CORPORATION (US) | 1980-11-04 | — | — | US | disclosed |
| US-4226872-A | Pyridyl esters of α-substituted amino acids | ZOECON CORPORATION (US) | 1980-10-07 | — | — | US | disclosed |
| US-4200758-A | 2,4-Imidazolidinedionylmethyl esters and thiolesters of anilino acids | ZOECON CORPORATION (US) | 1980-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090297476-A1 | NOVEL PEPTIDE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | VIP, HDGF, EIF2AK2 | MMP2 794/4885MAPK1 977/4885MMP1 756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.